Showing 1 results for Non-Alcoholic Fatty Liver Disease (nafld).
Saman Sargazi, Mahtab Ghasemi Toudeshkchouei, Abbas Rahdar, Aisha Rauf, Soheil Amani, Razieh Behzadmehr, Ana M. Diez-Pascual, Francesco Baino, Muhammad Bilal,
Volume 20, Issue 1 (3-2023)
Abstract
As a major global cause of liver disease, non-alcoholic fatty liver disease (NAFLD) is characterized by excessive hepatocellular accumulation of lipids in the liver, elevated levels of hepatic enzymes, and fibrotic evidence. The primary therapies for NAFLD are changing lifestyle or managing comorbid-associated diseases. Lately, nanotechnology has revolutionized the art of nanostructure synthesis for disease imaging, diagnosis, and treatment. Loading drugs into nanocarriers has been established as a promising strategy to extend their circulating time, particularly in treating NAFLD. In addition, considering a master modulator of adipogenesis and lysosomal biogenesis and function, designing novel nanostructures for biomedical applications requires using biodegradable materials. Various nanostructures, including inorganic nanoparticles (NPs), organic-based NPs, metallic nanocarriers, biodegradable polymeric nanocarriers, polymer-hybrid nanocarriers, and lipid-based nanocarriers have been designed for NAFLD treatment, which significantly affected serum glucose/lipid levels and liver function indices. NPs modified with polymers, bimetallic NPs, and superparamagnetic NPs have been used to design sensitive nanosensors to measure NAFLD-related biomarkers. However, certain limitations are associated with their use as diagnostic agents. The purpose of this review article is to shed light on the recent advancements in the field of nanomedicine for the early diagnosis, treatment, and prognosis of this progressive liver disease.
